ONCY
Oncolytics Biotech, Inc.

7,279
Mkt Cap
$120.43M
Volume
589,331.00
52W High
$1.51
52W Low
$0.3258
PE Ratio
-4.47
ONCY Fundamentals
Price
$1.21
Prev Close
$1.20
Open
$1.22
50D MA
$1.21
Beta
0.86
Avg. Volume
1.47M
EPS (Annual)
-$0.3026
P/B
26.20
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Oncolytics Biotech to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Oncolytics Biotech to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights Oncolytics Biotech to Host Conference Call to Discuss Fourth...
PR Newswire·8mo ago
News Placeholder
More News
News Placeholder
Investors Eye Biotech Sector as Cancer Therapy Market Surges
Investors Eye Biotech Sector as Cancer Therapy Market Surges Investors Eye Biotech Sector as Cancer Therapy Market Surges PR Newswire VANCOUVER, BC, Feb. 19, 2025 USA News Group News CommentaryIssued...
PR Newswire·8mo ago
News Placeholder
Oncolytics Biotech Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025
Oncolytics Biotech Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 Oncolytics Biotech Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 PR...
PR Newswire·8mo ago
News Placeholder
Oncolytics Biotech Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Oncolytics Biotech Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency Oncolytics Biotech Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid...
PR Newswire·8mo ago
News Placeholder
Oncolytics Biotech Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence
Oncolytics Biotech Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence Oncolytics Biotech Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following...
PR Newswire·9mo ago
News Placeholder
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year PR Newswire VANCOUVER, BC, Jan. 15, 2025 Issued on behalf...
PR Newswire·10mo ago
News Placeholder
Regulatory Approval Clears Path for Oncolytics Biotech to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data
Regulatory Approval Clears Path for Oncolytics Biotech to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data Regulatory Approval Clears Path for Oncolytics Biotech to...
PR Newswire·10mo ago
News Placeholder
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment PR Newswire VANCOUVER, BC, Dec. 26, 2024 USA News...
PR Newswire·10mo ago
News Placeholder
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options PR Newswire VANCOUVER, BC, Dec. 23, 2024 Issued on...
PR Newswire·10mo ago
News Placeholder
Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data
Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data Oncolytics Biotech Highlights 2024 Achievements and Prepares for an...
PR Newswire·10mo ago

Latest ONCY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.